Magazine Article | November 1, 2023

An Overview Of The 9 FDA Special Designations For Pipeline Drugs

Source: Life Science Leader

By Ryan Chandanais

The FDA employs various special designations to streamline and incentivize the advancement of drugs addressing medical gaps. While some designations can accelerate FDA timelines for NDAs and biologics license applications (BLAs), others may abbreviate the duration of clinical trials. This approach grants manufacturers an extended timeframe between drug launches and the eventual loss of exclusivity.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: